Synapse - Cancer Immunology, Immunotherapy

Cancer Immunology, Immunotherapy

Published by: Springer

People

Groups

Search Within

Results (1)

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)

Journal Article

Lacouture, M. E.; Morris, J. C.; Lawrence, D. P.; Tan, A. R.; Olencki, T. E.; Shapiro, G. I.; Dezube, B. J.; Berzofsky, J. A.; Hsu, F. J.; Guitart, J.
Cancer Immunology, Immunotherapy (2015)

Fulltext@MSK | Save

Cancer Immunology, Immunotherapy – authorized name for:

Name	ISSN / ISBN	Publisher
Cancer Immunology and Immunotherapy	978-3-642-14136-2	Springer Verlag
Cancer Immunology Immunotherapy	0340-7004	Springer
Cancer Immunology Immunotherapy	0340-7004	Unknown
Cancer Immunology Immunotherapy	0340-7004	Springer
Cancer Immunology Immunotherapy	0340-7004	Springer
Cancer Immunology Immunotherapy	0340-7004	Springer Verlag
Cancer Immunology Immunotherapy	03407004	Springer Verlag
Cancer Immunology Immunotherapy	03407004	Unknown
Cancer Immunology Immunotherapy	0340-7004	Springer Verlag
Cancer Immunology, Immunotherapy	0340-7004	Springer Verlag
Cancer Immunology, Immunotherapy	0340-7004	Springer Verlag
Cancer Immunology, Immunotherapy	0340-7004	Springer
Cancer Immunology, Immunotherapy	0340-7004	Springer
Cancer Immunology, Immunotherapy	03407004	Springer Verlag
Cancer Immunology, Immunotherapy	0340-7004	Springer
Cancer Immunology, Immunotherapy	03407004	2022, The Author(s), Under Exclusive Licence To Springer Verlag Gmbh Germany, Part of Springer Nature
Cancer Immunology, Immunotherapy	03407004	Springer Verlag
Cancer Immunology, Immunotherapy	03407004	Springer Verlag
Cancer Immunology, Immunotherapy	03407004	2018, Springer Verlag Gmbh Germany, Part of Springer Nature
Cancer Immunology, Immunotherapy	03407004	2019, The Author(s)
Cancer Immunology, Immunotherapy	03407004	Springer Verlag
Cancer Immunology, Immunotherapy	03407004	The Author(s)
Cancer Immunology, Immunotherapy	03407004	2022, The Author(s)
Cancer Immunology, Immunotherapy	03407004	2023, The Author(s)
Cancer Immunology, Immunotherapy	03407004	2023, The Author(s), Under Exclusive Licence To Springer Verlag Gmbh Germany, Part of Springer Nature
Cancer Immunology, Immunotherapy	03407004	Springer Verlag
Cancer Immunology, Immunotherapy	03407004	Springer Verlag Berlin Heidelberg
Cancer Immunology, Immunotherapy	03407004	Springer Verlag Berlin Heidelberg
Cancer Immunology, Immunotherapy	03407004	The Author(s) 2024
Cancer Immunology, Immunotherapy	0340-7004	Springer
Cancer Immunology, Immunotherapy	03407004	Springer Verlag
Cancer Immunology, Immunotherapy	0340-7004	Springer
Cancer Immunology, Immunotherapy	0340-7004	Springer
Cancer Immunology, Immunotherapy	03407004	Unknown
Cancer Immunology, Immunotherapy	03407004	Us Government